Session Information
2007 BIO International Convention
Click here to go to the previous page
The Great Debate: Acquisition or IPO?
Track
:
Finance
Program Code:
FIN090
Date:
Wednesday, May 9, 2007
Time:
11:00 AM to 12:30 PM
Location:
204 AB
CHAIR
:
Click the plus sign to see more detailed information
about each speaker.
Click the plus sign to see more detailed information
about each speaker.
SPEAKER
(S):
Barclay Kamb
Dr. Larry Fritz, PhD, President & CEO, Anadys Pharmaceuticals, Inc.
Leslie Williams, RN, BSN, MBA, President and CEO, Ventaira Pharmaceuticals, Inc.
Dennis Podlesak, Chief Executive Officer, Cerexa, Inc.
Description
The IPO has long been a Holy Grail for private biotechnology companies—the way to funding, late-stage trials and an eventual string of product launches to build the next Amgen, but a recent New York Times article reports that since October 2003, nearly six times as many biotechs chose acquisition over IPO. VCs and company representatives on this panel will debate the pros and cons of planning an IPO versus setting yourself up for acquisition, and will share key advice for each route.
Objectives:
Provide pros and cons for each exit option.
Examine case studies to demonstrate the pros and cons.
Discuss options in light of today's landscape.
Objectives:
Streaming Audio with
PowerPoint Slides
PowerPoint Slides
(Code: FIN090)
This session is a part of: